8:00 am Registration & Breakfast

8:50 am Chair’s Opening Remarks

9:00 am Drugs & Trials in the Cell Engager Space

Synopsis

Gain a detailed overview of the current preclinical and clinical landscapes with top flight analysis from the Beacon Bispecific team

  • Drugs Entered into the Clinic
  • Top Targets
  • Developers

9:30 am Advancements in BiTE Technology to Meet the Needs of Large Patient Populations

Synopsis

  • Discuss how this technology overcomes the challenge that certain immuno-oncology therapies and chemotherapies do not specifically target cancer cells through tumor-associated antigens
  • How does Amgen balance long-term benefits while managing the potential cost of high toxicity?

10:00 am pHLA Directed T Cell Engager

  • Nicolas Sabarth Head of Research Laboratory, Biotherapeutics Discovery & Cancer Immunology, Boehringer Ingelheim

Synopsis

  • Review key concepts in immunotherapy discovery
  • Discuss how the learnings that have been gained in exploring pHLA TCE

10:30 am Morning Networking & Coffee Break

11:30 am Hitting Multiple Solid Tumors with Specificity

  • Jeremy Myers Senior Vice President, EvolveImmune Therapeutics, Inc.

Synopsis

  • EVOLVE-101 is a first-in-category therapeutic for B cell malignancies and AML
  • EvolveImmune will move both programs rapidly to clinical trials

CRS Prediction & Management to Guarantee Patient Safety in the Clinic

12:00 pm Panel Discussion: The Relevance & Importance of CRS in Solid Tumors

Synopsis

  • Questioning which learnings from the advancements and approvals in liquid tumors are transferable to solid tumors
  • Evaluating if there is a risk of CRS in a solid tumor indication, what can be done to predict and mitigate it
  • Discuss whether CRS will present in a similar way for solid tumor patients compared to liquid tumors

12:30 pm Overview of CRS and Other Toxicities in Bispecific Trials

1:00 pm Networking & Lunch Break

2:00 pm Panel Discussion: The Trials & Tribulations of Bispecifics

Synopsis

  • Looking back at the problems bispecific antibody programs have faced with
  • Examine the strengths what strengths bispecifics are still known to have
  • Suggest what could be done in the early research and translational stages to mitigate these challenges, as well as whether sufficient tools exist to predict potential issues

Maximizing Effectiveness & Safety Through Rationally Designed Combinations

2:30 pm Interactive Worksheet Activity – Co-Engage, Co-stimulate or Combine?

Synopsis

Discuss at your tables the strengths vs. weaknesses of Co-Engagement, Co-Stimulation and Combinations from therapeutic and strategic perspectives. On your table will be a matrix worksheet for each of these perspectives to which your thoughts will be added. These will be collated into a post-event report document.

3:15 pm Roundtable Discussion: Making the Making the Best of a Bad Situation – Achieving Responses in Immune-Deficient Patients

Synopsis

  • Many patients have immune systems that have been depleted by multiple therapies. In lieu of opportunities to be an earlier line therapy, how can we ensure we maximize the opportunities that are available to us?
  • Explore which cell/therapy types are more likely to be most impacted by immune system exhaustion
  • Discuss the strategies that are currently in play to augment the immune system for improved response
  • Considering potential safety concerns these approaches could have

3:45 pm Closing Remarks & End of Conference